BCR and mantle cell lymphoma: We hypothesized that dual inhibition of AK-A plus BTK by inhibiting mitosis and the chronic active B-cell receptor (BCR) signaling, respectively, would be synergistic as anti-MCL therapy by disrupting the proliferation of MCL cells insensitive to BTK inhibition and enhancing cellular apoptosis.